ZIOP ZIOPHARM Oncology Inc

3.42
+0.31  (+10%)
Previous Close 3.11
Open 3.09
Price To Book 4.07
Market Cap 732,859,273
Shares 214,286,337
Volume 2,797,474
Short Ratio
Av. Daily Volume 1,760,616
Stock charts supplied by TradingView

NewsSee all news

  1. Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference

    BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the

  2. Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update

    – Regulatory discussions with FDA advance Ziopharm TCR-T IND process –– Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron's Libtayo®;Controlled IL-12 clinical data update at ASCO 2020 –– Work

  3. Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting

    BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as

  4. Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020

    BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a corporate update and

  5. Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019

    – Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 interim data due 1H 2020.
Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)
Refractory glioblastoma multiforme (GBM)
Phase 2 patient screening has commenced - noted March 2, 2020.
Sleeping beauty - TCR-T cell therapy
Solid tumors
Phase 2 enrolment to be completed 1H 2020. Initial data due at ASCO May 29, 2020.
Ad-RTS-hIL-12 plus veledimex plus Libtayo (ASCO)
Refractory glioblastoma multiforme (GBM)

Latest News

  1. Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference

    BOSTON, May 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the

  2. Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update

    – Regulatory discussions with FDA advance Ziopharm TCR-T IND process –– Enrollment on track in Controlled IL-12 phase 2 clinical trial with Regeneron's Libtayo®;Controlled IL-12 clinical data update at ASCO 2020 –– Work

  3. Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting

    BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that it will be presenting data from its Controlled IL-12 program, or Ad-RTS-hIL-12 plus veledimex (Ad+V), both as

  4. Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020

    BOSTON, April 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced the Company will host a conference call and webcast on Thursday, May 7, at 4:30 pm EDT to provide a corporate update and

  5. Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019

    – Emergence of TCR program, Controlled IL-12 data, strengthened team highlight 2019 – – Balance sheet strengthened; cash of approximately $177 million funds operations to mid-2022 – – Clinical trial milestones and data

  6. Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast

    BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at

  7. Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020

    BOSTON, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that management will host a conference call and webcast on Monday, March 2, at 4:30 p.m. ET to provide a corporate update

  8. Ziopharm Oncology Announces Pricing of Public Offering of Common Stock

    BOSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced the pricing of an underwritten public offering of 27,826,086 shares of its common stock at a public offering price of

  9. Ziopharm Oncology Announces Proposed Public Offering of Common Stock

    BOSTON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the

  10. Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals

    – Encouraging long-term outcome data after infusion of Sleeping Beauty-modified CAR-T published in Blood – – TCRs targeting mutations in TP53 obtained from T cells in peripheral blood to overcome need for surgical

  11. Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast

    BOSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at

  12. Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares

  13. Ziopharm Oncology Presents Pre-Clinical Data Validating "Rapid Personalized Manufacture" (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

    – Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells – – T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer – BOSTON, Dec. 08, 2019 (GLOBE

  14. Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

    – Controlled IL-12 evaluated as monotherapy in an expanded number of patients reinforced favorable safety profile and initial data consistent with immune-mediated anti-tumor effects – – Controlled IL-12 can be combined

  15. Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference

    BOSTON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that the Company's presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to

  16. Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast

    BOSTON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the

  17. Ziopharm Oncology Reports Third Quarter 2019 Financial Results

    – Phase 2 trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of

  18. Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019

    BOSTON, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7, at 4:30 p.m. ET to provide a corporate

  19. Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors

    – Industry veteran with 20+ years of global oncology drug development leadership –   – Current CMO at Agios Pharmaceuticals; Former VP of Product Development, Oncology at Genentech –   BOSTON, Oct. 15, 2019

  20. Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T

    – Phase 1 clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm's Sleeping Beauty platform –   – Rapid personalized manufacture of CD19-specific CAR-T for investigation in

  21. Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    BOSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the

  22. Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares